Европска Унија - Енглески - EMA (European Medicines Agency)

novartis europharm ltd - aliskiren, amlodipine - hypertension - agents acting on the renin-angiotensin system - rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.

Европска Унија - Енглески - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.

Европска Унија - Енглески - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.riprazo hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.rirpozo hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

Европска Унија - Енглески - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.

Европска Унија - Енглески - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.sprimeo hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.sprimeo hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

Европска Унија - Енглески - EMA (European Medicines Agency)

novartis europharm ltd - ofatumumab - leukemia, lymphocytic, chronic, b-cell - monoclonal antibodies - previously untreated chronic lymphocytic leukaemia (cll): arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with cll who have not received prior therapy and who are not eligible for fludarabine-based therapy. relapsed cll: arzerra is indicated in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed cll. refractory cll: arzerra is indicated for the treatment of cll in patients who are refractory to fludarabine and alemtuzumab.,

Европска Унија - Енглески - myHealthbox

novartis europharm limited - indacaterol, glycopyrronium bromide - inhalation powder, hard capsule - 110 microgram indacaterol and 50 microgram glycopyrronium - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)

Европска Унија - Енглески - myHealthbox

novartis europharm limited - indacaterol, glycopyrronium - inhalation powder, hard capsule - 85 micrograms/43 micrograms - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)

Европска Унија - Енглески - EMA (European Medicines Agency)

novartis europharm ltd - serelaxin - heart failure - other vasodilators used in cardiac diseases - treatment of acute heart failure

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).